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Telomerase Activity and the Risk of Lung Cancer
Telomerase play a key role in the maintenance of telomere length and chromosome 
integrity. We have evaluated the association between telomerase activity and the risk of 
lung cancer in peripheral blood. Telomerase activity in peripheral blood mononuclear cells 
was measured by a PCR-designed telomeric repeat amplification protocol in 63 lung cancer 
patients and 190 healthy controls that were matched for age, gender, and smoking status. 
Telomerase activity was significantly lower in the lung cancer patients than in controls 
(mean ± standard deviation; 1.32 ± 1.65 vs 2.60 ± 3.09, P < 1 × 10
-4). When telomerase 
activity was categorized into quartiles based on telomerase activity in the controls, the risk 
of lung cancer increased as telomerase activity reduced (Ptrend = 1 × 10
-4). Moreover, when 
the subjects were categorized based on the median value of telomerase activity, subjects 
with low telomerase activity were at a significantly increased risk of lung cancer compared 
to subjects with high telomerase activity (adjusted odds ratio = 3.05, 95% confidence 
interval = 1.60-5.82, P = 7 × 10
-4). These findings suggest that telomerase activity may 
affect telomere maintenance, thereby contributing to susceptibility to lung cancer.
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INTRODUCTION
Telomeres consist of long, repetitive sequences of TTAGGG and 
an associated telomere-binding protein complex (shelterin) (1). 
The telomeres of somatic cells progressively shorten with each 
mitotic division, owing to the inability of DNA polymerase to 
fully replicate the 3´ end of the DNA strand. Telomeres function 
to cap the ends of chromosomes and protect chromosomes from 
degradation, end-to-end fusion, and irregular recombination. 
Thus, progressive telomere shortening interferes with the forma-
tion of telomeric caps, which ultimately leads to chromosomal 
instability and can increase tumor formation by increasing the 
rate of mutation of oncogenes and tumor suppressor genes (2-
5). Telomerase, a RNA-dependent DNA polymerase that consists 
of a template RNA (TERC) and a catalytic reverse transcriptase 
(TERT), adds telomeric DNA repeats de novo after each cell di-
vision, thus maintaining telomere length and function despite 
the telomere attrition that normally occurs during chromosom-
al replication (6, 7).
  Several studies have documented considerable variation in 
telomere length and telomerase activity of peripheral blood lym-
phocytes among healthy individuals of the same age (8, 9). The 
heritability of telomere length has been linked to regions on chro-
mosomes 3, 10, 14, and 18 (10-13). In addition, several cross-sec-
tional and prospective studies have observed that individuals 
who had shorter telomeres are at an increased risk for the devel-
opment of a variety of human cancers, including lung cancer 
(14, 15). Considering these observations, we have hypothesized 
that the heritable variation of telomerase activity may affect the 
risk of lung cancer. To test this hypothesis, we evaluated the as-
sociation between telomerase activity of peripheral blood mono-
nuclear cells (PBMCs) and lung cancer risk in a case-control 
study. 
MATERIALS AND METHODS
Study population
This case-control study included 63 patients with lung cancer 
and 190 healthy controls. The cases were recruited from patients 
who were newly diagnosed with primary lung cancer between Jeon H-S, et al.  •  Telomerase Activity and the Risk of Lung Cancer
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January and July 2004 at Kyungpook National University Hospi-
tal, in Daegu, Korea. The control subjects were randomly se-
lected from a pool of healthy volunteers who visited the general 
health check-up center at Kyungpook National University Hos-
pital during the same period. We randomly selected 190 control 
subjects that were matched to the cases based on age ( ± 5 yr), 
gender, and smoking status. All of the cancer patients and the 
controls were ethnic Koreans who resided in Daegu City or the 
surrounding regions. 
PBMC isolation and cell culture
Changes in telomerase activity were measured in PBMCs from 
lung cancer patients and healthy controls. PBMCs were sepa-
rated from serum and red blood cells by gradient density cen-
trifugation through Ficoll-Paque (GF Health Care, Piscataway, 
NJ, USA) and stored in liquid nitrogen. The frozen lymphocytes 
were thawed and cultured in RPMI 1640 media supplemented 
with 20% heat-inactivated fetal bovine serum and 112.5 μg/mL 
of phytohemagglutinin. Cells were incubated at 37°C for 72 hr in 
a humidified atmosphere containing 5% CO2. PBMCs proteins 
were obtained by adding lysis buffer and centrifuged at 16,000 g 
for 10 min at 4°C. The protein concentration was measured us-
ing the Bio-Rad Protein Assay (Bio-Rad, Richmond, CA, USA).
Measurement of telomerase activity 
Telomerase activity in PBMCs was detected using a quantitative 
telomerase detection kit (Allied Biotech, Inc., Germantown, MD, 
USA) according to the manufacturer’s protocol, which is based 
on a PCR-designed telomeric repeat amplification protocol. 
Briefly, telomerase in the cell extract from 1 × 10
5 cells of PBMCs 
added telomeric repeats (TTAGGG) onto the 3´ end of the sub-
strate oligonucleotide and QTD premix (Allied Biotech), and 
was amplified with a LightCycler480 machine (Roche Applied 
Science, Indianapolis, IN, USA). The generated PCR products 
are directly detected by measuring the increase in fluorescence 
caused by binding of SYBR Green to double-stranded DNA. A 
heat-inactivated cell extract served as a negative control. The 
real-time PCR conditions were as follows: telomerase reaction 
for 20 min at 25°C, PCR initial activation step for 10 min at 95°C, 
followed by 45 cycles of denaturation for 15 sec at 95°C, anneal-
ing for 15 sec at 60°C, extension for 15 sec at 72°C.
Statistical analysis 
Telomerase activity was analyzed as continuous and categorial 
variables. ANOVA or a t-test was used to evaluate the differences 
in telomerase activity as a continuous variable by case-control 
status, age, gender, and smoking history (never-, or ever-smok-
er). As a categorical variable, the quartile value of telomerase 
activity, according to the distribution of telomerase activity in 
control subjects, was used to compare the differences between 
the cases and controls. In addition, telomerase activity was di-
chotomized at the median value in control subjects. The cate-
gorized telomerase activity of the cases and controls were com-
pared using a chi-squared test. Unconditional logistic regression 
analysis was used to calculate the odds ratios (ORs) and 95% con-
fidence intervals (CIs), with adjustment for possible confound-
ers (gender and smoking status as nominal variables, and age 
and pack-years of smoking as continuous variables). The homo-
geneity test was conducted to compare the difference between 
telomerase activity-related OR of different groups. All of the anal-
yses were performed using Statistical Analysis Software for Win-
dows, version 8.12 (SAS institute, Cary, NC, USA). 
Ethics statement
This study was approved by the Institutional Review Board of 
Kyungpook National University Hospital (Approval No., KNUH-
BIO_10-1017) and written informed consent was obtained from 
each participant.
 
RESULTS
The demographics of the cases and controls enrolled in the cur-
rent study are shown in Table 1. There were no significant differ-
ences in the distribution of mean age, gender, or smoking status 
between the cases and controls; thus, adequate matching was 
conducted based on these three variables. However, the num-
ber of pack-years in ever-smokers was significantly higher in the 
cases than in the controls (mean ± standard deviation (SD): 
36.4 ± 17.6 vs 26.4 ± 11.9 pack-years; P < 0.001). 
  Telomerase activity was significantly lower in lung cancer pa-
tients than in healthy controls (mean ± SD: 1.31 ± 1.65 vs 2.60 ±  
3.09, P < 1 × 10
-4). The effects of covariates on telomerase activ-
ity in the cases and controls are shown in Table 2. There were no 
significant differences in telomerase activity according to age, 
gender and smoking status in the case or control groups. When 
telomerase activity in the case group was compared with the 
control group, telomerase activity was significantly lower in the 
cases than the controls for each of the subgroups evaluated, age, 
gender, and smoking status. 
  Table 3 shows the risk of lung cancer related to telomerase ac-
tivity. When the subjects were categorized into quartiles of telom-
erase activity based on the telomerase activity distribution of 
the controls, with the fourth (highest) quartile used as the refer-
Table 1. Characteristics of the study population
Variables Cases (n = 63) Controls (n = 190)
Age (yr) 58.6 ± 7.8 56.9 ± 6.9
Gender
   Male
   Female
  
 47 (74.6)*
16 (25.4)
 
136 (71.6)
  54 (28.4)
Smoking status
   Ever
   Never
 
46 (73.1)
17 (26.9)
 
116 (61.1)
  74 (38.9)
*Numbers in parenthesis, percentage.Jeon H-S, et al.  •  Telomerase Activity and the Risk of Lung Cancer
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ence category, the adjusted OR for lung cancer was increased 
from 1.65 (95% CI, 0.55-4.96) to 3.38 (95% CI, 1.23-9.26) to 4.74 
(95% CI, 1.77-12.71) as the telomerase activity decreased from 
the 3rd to the 1st quartile (Ptrend = 6 × 10
-4), respectively. When 
the median value of telomerase activity in the control subjects 
was used as the cut-off between high and low telomerase activ-
ity, individuals with low telomerase activity were at a significant-
ly increased risk of lung cancer compared to subjects with high 
telomerase activity (adjusted OR, 3.05; 95% CI, 1.60-5.82; P =  
7 × 10
-4). 
  The effect of telomerase activity on the risk of lung cancer was 
further examined after stratifying the subjects according to age, 
Table 2. Effects of covariates on telomerase activity by case-control status
Variables
Cases Controls
     P*
No. Mean (SD) No. Mean (SD)
Overall 63 1.32 ± 1.65 190 2.60 ± 3.09 < 0.001
Age (yr)
   < 58
   ≥ 58
   P*
 
24
39
 
1.08 ± 1.71
1.46 ± 1.61
   0.39
 
105
85
 
2.61 ± 3.08
2.59 ± 3.12
0.98
 
0.001
0.01
Gender
   Male
   Female
   P*
 
47
16
 
1.30 ± 1.55
1.36 ± 1.97
0.91
   
136
54
 
2.47 ± 2.87
2.94 ± 3.61
0.40
 
0.001
0.03
Smoking status
   Never
   Ever
   P*
 
17
46
 
1.42 ± 1.94
1.28 ± 1.55
0.76
 
74
116
 
3.15 ± 3.84
2.25 ± 2.46
0.08
 
0.01
0.01
*P value using two-sided one-way ANOVA or t-test.
Table 3. Associations between telomerase activity and lung cancer risk
Telomere status
Cases (n = 63) Controls (n = 190)
OR (95% CI)* P*
No. (%) No. (%)
Categorized by quartile in controls
   4th quartile
   3rd quartile
   2nd quartile
   1st quartile
   P
†
   Ptrend
 
6 (9.5)
10 (15.9)
20 (31.7)
27 (42.9)
4 × 10
-3
 
 
49 (25.8)
46 (24.2)
48 (25.3)
47 (24.7)
 
 
1.00
1.65 (0.55-4.96)
3.38 (1.23-9.26)
  4.74 (1.77-12.71)
 
6 × 10
-4
 
 
0.37
0.02
0.01
 
 
Categorized by median in controls
   High
   Low
   P
†
 
16 (28.6)
47 (71.4)
6 × 10
-4
 
95 (50.0)
95 (50.0)
 
1.00
3.05 (1.60-5.82)
 
 
7 × 10
-4
*ORs (95% CIs) and corresponding P values were calculated by unconditional logistic regression, adjusted for age, gender and pack-years of smoking; 
†Chi-square test for dis-
tribution between the cases and controls.
Table 4. Lung cancer risk estimates for telomerase activity by selected variables
Variables
Cases (n = 63) Controls (n = 190) OR (95% CI)*
for low activity
P* P H
†
High Low High Low
Age (yr)
   < 58
   ≥ 58
 
  3 (12.5)
13 (33.3)
 
21 (87.5)
26 (66.7)
 
55 (52.4)
45 (47.1)
 
50 (47.6)
40 (52.9)
 
  7.96 (2.20-28.68)
1.58 (0.70-3.55)
 
0.01
0.27
 
 
0.04
Gender
   Male
   Female
 
12 (25.5)
  4 (25.0)
 
35 (74.5)
12 (75.0)
 
65 (47.8)
30 (55.6)
 
71 (52.2)
24 (44.4)
 
2.69 (1.26-5.73)
   3.91(1.09-13.93)
 
0.01
0.04
 
 
0.62
Smoking status
   Never
   Ever
 
  5 (29.4)
11 (24.0)
 
12 (70.6)
35 (76.0)
 
41 (55.4)
54 (46.5)
 
33 (44.6)
62 (53.5)
 
2.92 (0.90-9.47)
2.97 (1.36-6.49)
 
0.07
0.01
 
 
0.98
Histological type
   Non-small cell carcinoma
   Small cell carcinoma
 
13 (25.0)
  3 (27.3)
 
39 (75.0)
  8 (72.7)
 
95 (50.0)
95 (50.0)
 
95 (50.0)
95 (50.0)
 
3.25 (1.62-6.53)
2.46 (0.62-9.75)
 
0.001
0.20
 
 
0.72
*ORs (95% CIs) and corresponding P values were calculated using unconditional logistic regression analysis, adjusted for age, gender and status of smoking when appropriate; 
†Test for homogeneity.Jeon H-S, et al.  •  Telomerase Activity and the Risk of Lung Cancer
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gender, smoking status, and tumor histology. When the subjects 
were stratified by the median age, the effect of telomerase activ-
ity on the risk of lung cancer was significant in younger individ-
uals (adjusted OR, 7.96; 95% CI, 2.20-28.68; P = 0.01), but not in 
older individuals (adjusted OR, 1.58; 95% CI, 0.70-3.55; P = 0.27; 
P value of test for homogeneity [PH] = 0.04) (Table 4). When strat-
ified by gender and smoking status, the effect of low telomerase 
activity on the risk of lung cancer was not significantly different 
between males and females, as well as never- and ever-smokers 
(PH = 0.62 and 0.98, respectively). When the analysis was strati-
fied by tumor histology, the effect of low telomerase activity was 
significant for non-small cell lung cancer (adjusted OR, 3.92; 95% 
CI, 1.62-6.53; P = 0.001), but not for small cell lung cancer (ad-
justed OR, 2.46; 95% CI, 0.62-9.75; P = 0.20, PH = 0.72) (Table 4). 
DISCUSSION
In this study, we investigated the association between the telom-
erase activity of PBMCs and the risk of lung cancer. We showed 
that individuals with low telomerase activity were at a signifi-
cantly increased risk of lung cancer, and that the risk of lung can-
cer increased as the telomerase activity decreased. These find-
ings suggest that telomerase activity may affect telomere main-
tenance, thereby contributing to the susceptibility to lung cancer. 
  Telomerase is overexpressed in the vast majority of human 
cancers (16, 17). Because telomerase maintains telomeres, the 
finding of high telomerase activity in cancers might lead to the 
hypothesis that longer inherited telomere length is causally re-
lated to human cancer (5, 18, 19). However, in contrast to this 
hypothesis, studies of telomerase knockout mice found that telo-
mere shortening induces chromosome instability, which is per-
petuated through fusion-bridge-breakage cycles that increases 
the risk of cancer development (20-23). Moreover, several stud-
ies have observed that individuals with shorter telomeres are at 
an increased risk for the development of various human cancers 
(14, 15, 24). In the present study, we found that low telomerase 
activity in PBMCs was associated with a significantly increased 
risk of lung cancer. This finding suggests that low telomerase ac-
tivity may lead to impaired telomere length maintenance, which 
would increase the risk of lung cancer. Our finding corroborates 
previous observations which have demonstrated a link between 
shorter telomere length and cancer (14, 15, 20-24).
  Recently, a genome-wide association study has shown that a 
chromosomal region (5p15.33) that contains TERT, a major de-
terminant of telomerase activity, contributes to the susceptibili-
ty to lung cancer (25). In addition, polymorphism(s) in the pro-
moter of the TERT gene have been shown to affect TERT expres-
sion, and thereby modulate telomere length and lung cancer 
risk (26-28). Furthermore, common variants near TERC, which 
encodes the telomerase RNA component, have been shown to 
be associated with telomere length in a genome-wide associa-
tion analysis (12). These studies indicate that telomerase activi-
ty may affect telomere length, and thereby influence the risk of 
lung cancer, further supporting our finding of an association 
between telomerase activity and the risk of lung cancer.  
  An interesting finding of the current study is that telomerase 
activity had a more pronounced association in younger than in 
older individuals. Although the reason for the observed age-de-
pendent difference in the risk conferred by telomerase activity 
remains to be elucidated, this difference may be attributed to 
age-related changes in telomere length and telomerase activity. 
It has been shown that telomere length and telomerase activity 
decrease in a linear fashion with age, and the levels are signifi-
cantly lower in older people (5, 25, 26). Therefore, it is possible 
that the effect of variation in telomerase activity on telomere 
length may be less in older individuals than in younger individ-
uals. Several studies have observed a similar finding; specifical-
ly, the effect of inheriting telomere length on the risk of lung can-
cer was more pronounced in younger subjects than in older sub-
jects (14, 15, 24). The current study, along with previous pub-
lished studies investigating the relationship between telomere 
length and lung cancer risk (14, 15, 24), suggest that telomere 
dysfunction may play a greater role in the development of lung 
cancer in younger individuals than older individuals. However, 
it is possible that our finding was due to chance because of the 
relatively small number of subjects in the subgroups. Therefore, 
larger studies should be conducted to confirm this finding. 
  A number of limitations in the present study need to be ad-
dressed. One such limitation was the small sample size, which 
did not allow for validation testing in a separate cohort or for re-
liable subgroup analysis. Therefore, our results need to be repli-
cated to validate the observed association. Furthermore, the age 
ranges in our studies were limited, reducing our ability to ob-
serve a significant correlation with increasing age and decreas-
ing telomerase activity. In addition, one must consider potential 
biases that might influence the results of hospital-based case-
control studies, primarily selection and information biases.
  In conclusion, we showed that low telomerase activity in PBMCs 
is associated with a significantly increased risk of lung cancer. It 
is interesting to note that in the current study, we demonstrated 
that the effect of low telomerase activity on the risk of lung can-
cer was more pronounced in younger individuals than older in-
dividuals. These results suggest that variation in telomerase ac-
tivity may contribute to a genetic predisposition to lung cancer 
by influencing telomere length maintenance. However, this is 
the first case-control study investigating the association between 
telomerase activity and the risk of cancer. Therefore, additional 
studies are required to confirm the findings herein.
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